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a b s t r a c t
The non-structural protein-1 (NS1) of inﬂuenza A virus binds the p85β subunit of phosphoinositide 3-
kinase (PI3K) to induce PI3K activity in the infected cells. Some virus strains encode NS1 containing a
motif that binds tightly to the SH3 domain of the cellular adapter proteins Crk and CrkL to potentiate
NS1-induced PI3K activation. Here we show that this potentiation involves reorganization of the natural
CrkL–p85β complex into a novel trimeric complex where NS1 serves as a bridging factor. Of note, NS1
proteins that lack the SH3 binding capacity can also associate with CrkL, but in a less stable trimeric
complex mediated by p85β. The data presented here establish Crk proteins as general host cell cofactors
of NS1, and show that the enhanced PI3K activation by SH3 binding-competent NS1 variants is mediated
by a more efﬁcient tethering of Crk proteins to the NS1–PI3K complex.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A virus belongs to the Orthomyxoviridae family of
enveloped viruses (Palese and Shaw, 2007). Its genome is orga-
nized into eight single stranded negative-sense RNA segments and
encodes up to 12 different proteins (Medina and Garcia-Sastre,
2011). The non-structural protein-1 (NS1) is a multifunctional
virulence factor that is expressed at high levels in infected cells.
The multiple protein binding motifs and conformational plasticity
of NS1 enables it to interact with a plethora of host cell factors
(Hale, 2014).
NS1 is the key innate immunity evasion factor of inﬂuenza
viruses, and can hinder the interferon response via multiple
mechanisms (Krug and Garcia-Sastre, 2013). In addition, NS1
contributes to activation of the phosphoinositide 3-kinase (PI3K)
signaling in inﬂuenza A virus-infected cells. NS1 binds speciﬁcally
to the regulatory PI3K subunit p85β (Hale et al., 2006; Shin et al.,
2007) via an interaction that involves the NS1 residues Tyr89 and
Pro164 contacting the linker region between the two Src-
homology-2 (SH2) domains of p85β (Hale et al., 2010). Together
biochemical and structural studies on this interaction have led to a
model in which NS1 activates PI3K catalytic activity both by
neutralizing a negative regulatory element in the inter-SH2 region
of p85β as well as via direct contacts with the catalytic PI3K
subunit p110 (Hale et al., 2008, 2010).
Activation of PI3K signaling is not speciﬁc for IAV infection, and
instead is a common theme observed in host cell interactions of a
variety of RNA and DNA viruses. Increased PI3K activity can beneﬁt
viral replication via several mechanisms, including promotion of
viral entry, enhanced viral replication and gene expression, and
blocking of premature apoptosis of the host cell (Buchkovich et al.,
2008; Cooray, 2004; Dunn and Connor, 2012; Ehrhardt and
Ludwig, 2009), but has also been shown to be involved in
induction of antiviral innate immunity (Hrincius et al., 2011).
Nevertheless, the net effect of PI3K activity on IAV replication is
typically positive, as demonstrated by reports on profound sup-
pression of viral replication observed upon treatment of infected
cultures with PI3K inhibitors (Ehrhardt et al., 2006; Hale et al.,
2006).
While NS1 proteins from most if not all inﬂuenza A viruses are
capable of inducing at least some level of PI3K activation, our
studies have revealed that the 1918 pandemic inﬂuenza virus and
many avian IAVs are exceptionally potent PI3K activators
(Heikkinen et al., 2008). This distinct capacity was found to be
due to the presence of a functional SH3 domain-binding site close
to the C-termini of these NS1 proteins, which is lacking from NS1
proteins of inﬂuenza A strains causing seasonal epidemics in
humans.
Although the p85β protein also contains an SH3 domain, we
could not observe any binding of NS1 to this SH3 domain
(Heikkinen et al., 2008). Instead, we found that the NS1 SH3-
binding motif mediated strong and selective binding to the
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2015.06.009
0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Correspondence to: Department of Virology, University of Helsinki, Haartma-
ninkatu 3, PO Box 21, FIN-00014 Helsinki, Finland. Fax: þ358 9 191 26491.
E-mail address: kalle.saksela@helsinki.ﬁ (K. Saksela).
Virology 484 (2015) 146–152
aminoterminal SH3 domains of the two related adapter proteins,
Crk and CrkL (Heikkinen et al., 2008). In the following we use the
term Crk(L) for all Crk-family proteins, and CrkI, CrkII, or CrkL only
when speciﬁcally referring to one of them. SH3-dependent bind-
ing of NS1 to Crk(L) has subsequently been conﬁrmed by Ehrhardt
and colleagues, who also reported on the role of this interaction in
suppression of the JNK–ATF2 pathway (Hrincius et al., 2010).
Moreover, a functional Crk(L) binding motif has also been linked
to NS1-induced increased in cell viability in a complex also
involving NS1-binding protein-1 (Miyazaki et al., 2013), as well
as in dissociation of cellular Crk–Abl protein complexes and in
supression of the tyrosine kinase activity of Abl (Hrincius et al.,
2014).
Crk proteins are involved in PI3K signaling by binding to a
proline-rich motif in p85 via their N-terminal Crk(L) SH3 domain
(Brehme et al., 2009; Gelkop et al., 2001; Sattler et al., 1996). This
interaction has been studied especially regarding its role in PI3K
regulation upon immune cell activation. Studies in T cells have
shown that the interaction between Crk and p85 is coordinated and
facilitated by the ubiquitin ligase Cbl, which can engage in addi-
tional interactions both with Crk and p85 (Gelkop et al., 2001). The
Crk–p85–Cbl protein complex has also been characterized as an
important co-factor in oncogenic signaling by the Bcr–Abl fusion
protein in chronic myeloid leukemia (Sattler et al., 1996). Indeed, an
extensive proteomic characterization of the molecular network
involved in Bcr–Abl function by Superti-Furga and colleagues
identiﬁed Crk, p85, and Cbl among the seven most highly inter-
connected core components of this signaling network (Brehme et
al., 2009).
In order to elucidate the biochemical mechanism underlying
the PI3K superactivation by the SH3 binding-competent NS1
proteins we now have characterized in detail the mutual interac-
tion between NS1, p85β, and CrkL. Because both NS1 and p85β
interact with the Crk proteins via the same N-terminal Crk(L) SH3
domain it was of speciﬁc interest to investigate whether a trimeric
complex involving p85β, Crk(L) and NS1 can form.
Results
Association of different Crk proteins with NS1 and p85β
The family of Crk adapter proteins includes three members,
CrkI, CrkII, and CrkL. Of these CrkII (40 kDa) and CrkI (28 kDa) are
products of the same gene, whereas CrkL (39 kDa) is encoded by a
different gene. CrkII and CrkL consist of one SH2 and two SH3
domains, while CrkI is truncated before the second SH3 domain
due to alternative mRNA splicing (Fig. 1a).
To extend our previous ﬁndings on NS1/Crk(L) binding
(Heikkinen et al., 2008), we compared the capacity of these three
different Crk proteins to interact with a representative avian NS1
protein containing a functional SH3 binding site (NS1 from A/
Mallard/Netherlands/12/2000/H7N3; “Mallard” in the following).
To examine the role of NS1 SH3 binding, we also included in these
experiments a mutated version of Mallard NS1 protein (NS1-
AxxA), carrying an SH3 binding site disrupted by alanine substitu-
tion of two critical proline residues (P212 and P215). As shown in
Fig. 1b, NS1 associated readily with CrkI, CrkII, as well as CrkL,
correlating with the presence of an N-terminal SH3 domain in all
of these Crk proteins (Fig. 1a). In contrast, none of the Crk proteins
co-precipitated the SH3 binding-deﬁcient NS1-AxxA. The blotting
data shown in Fig. 1b are representative of several experiments,
and all results shown have been reproduced at least three times.
The same holds true for the blotting data shown in Figs. 2, 4, 5 and
6.
Relative roles of p85β and Crk-SH3 binding in PI3K activation by NS1
Hale and colleagues reported the critical contribution of the
tyrosine 89 of NS1 in direct binding to the regulatory PI3K subunit
p85β (Hale et al., 2006). On the other hand, we have shown that
NS1 containing a functional Crk-SH3 binding site show greatly
enhanced PI3K activation compared to SH3 binding-deﬁcient NS1
(Heikkinen et al., 2008). To investigate if the increased PI3K
activation provided by NS1 SH3 binding was directly coupled to
the NS1–p85β interaction or represented an independent regula-
tory event, we compared the effects of the AxxA (P212A/P215A;
disrupting Crk SH3 binding) and Y89F (disrupting p85β binding)
mutations.
In agreement with our earlier study (Heikkinen et al., 2008) we
found that the PI3K-activating capacity of Mallard NS1 (induction
of Akt phosphorylation) was reduced but not abrogated by the
AxxA mutation (Fig. 2a). By contrast, the Y89F mutant NS1 was
completely inactive in inducing Akt phosphorylation. Thus, we
conclude that Crk(L) recruitment by NS1 indeed serves to enhance
PI3K activation triggered by binding of NS1 to p85β, but this
enhancement remains entirely dependent on the latter
interaction.
Rearrangement of the endogenous p85β/CrkL complex by NS1
Because p85 binds not only to NS1 (Hale et al., 2006; Shin et al.,
2007) but is also an established interaction partner of the Crk
proteins (Brehme et al., 2009; Sattler et al., 1996, 1997) we
examined the association of p85β with CrkL in untransfected cells
and in cells transfected with the mutant NS1 proteins. Indeed,
p85β could be readily co-precipitated with CrkL from untrans-
fected cells that did not express any NS1 (Fig. 2b, leftmost lane).
Transfection of the CrkL binding-competent (WT) or incompetent
(AxxA) NS1 proteins did not signiﬁcantly inﬂuence the net
association of p85β with CrkL. However, transfection of the Y89F
mutant of NS1 (which is CrkL binding-competent but p85β
binding-deﬁcient) potently inhibited p85β/CrkL association. Since
Fig. 1. All Crk proteins have a comparable and SH3 domain-dependent capacity to
bind NS1. (a) Domain organization of CrkI, CrkII, and CrkL. (b) Co-precipitation of
wild-type (WT) and SH3 binding deﬁcient mutant (AxxA) Mallard NS1 proteins
with CrkI, CrkII, and CrkL from 293T cells. Crk proteins fused with a biotinylation
domain were cotransfected into cells with myc-tagged NS1 proteins. The amounts
of NS1 in the transfected lysates (bottom panel) or co-precipitated with Crk
proteins by streptavidin-coated beads (middle panel) were examined by anti-Myc
Western blotting. Equal precipitation of the biotinylated Crk proteins was con-
ﬁrmed by blotting with labeled streptavidin (top panel).
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p85β and NS1 compete for the same N-terminal SH3 domain of
CrkL, this observation suggested that NS1 could displace p85β
from binding to CrkL due to a higher afﬁnity for the CrkL SH3
domain.
To directly demonstrate that NS1 could displace p85β from a
preformed p85β–CrkL complex, we co-transfected cells with CrkL
and p85β without NS1, and added increasing amounts of recom-
binant NS1–Y89F into a lysate of these cells to examine whether
p85β or NS1 co-precipitated with CrkL. As shown in Fig. 2c
recombinant NS1–Y89F displaced p85β from its complex with
CrkL in a dose-dependent manner. The highest dose (12 μg) of
NS1–Y89F (corresponding to a 4-fold molar excess of p85β in the
lysate) completely abrogated association of p85β with CrkL. By
contrast, 12 μg of NS1-AxxA had no effect. As could be predicted, a
similar displacement of 85β from the complex with CrkL by wild-
type NS1 could be also demonstrated when NS1–p85β binding
was prevented by speciﬁc mutations in p85β (p85β-V573M)
(Supplementary Fig. 1).
These results suggested that co-precipitation of p85β with CrkL
observed in cells expressing wild-type NS1 (Fig. 2b) was probably
not direct, but instead indirectly mediated via the dual capacity of
NS1 to bind both CrkL and p85β, thus indicating a scenario where
the NS1-mediated enhancement of PI3K activation would involve
a rearrangement of the natural CrkL–p85β complex and lead to
formation of a trimeric CrkL–NS1–p85β complex (where NS1 is
the bridging factor; see Fig. 3). Assembly of such a trimeric
complex (as opposed to separate CrkL–NS1 and NS1–p85β com-
plexes) is enabled by the abundant cellular expression of CrkL.
On the other hand, based on the capacity of Crk(L), p85, and
NS1 to form dimeric complexes (see Fig. 3a), one could hypothe-
size that the complex of SH3 binding-deﬁcient NS1 with p85β
should also contain CrkL, thus representing an alternative trimeric
CrkL–p85β–NS1 complex (where p85β is the bridging factor).
Seemingly in conﬂict with this assumption, only the NS1
proteins capable of direct CrkL binding (WT and Y89F) but no
NS1-AxxA were found in anti-CrkL immunocomplexes (Fig. 2b).
Since this could be explained by a modest afﬁnity of the CrkL SH3
domain for p85β and/or a low abundance of p85β compared to
CrkL and NS1, we examined if overexpression of p85β would allow
us to detect p85β-mediated bridging of CrkL and NS1-AxxA. Thus,
we co-transfected increasing amounts of p85β into cells together
with a constant amount of wild-type NS1 or NS1-AxxA. As
expected, coprecipitation of wild-type NS1 with CrkL was already
efﬁcient in the absence of p85β transfection, and did not sig-
niﬁcantly change upon ectopic p85β expression (Fig. 4a). By
contrast, increasing amounts of p85β enabled coprecipitation of
NS1-AxxA with CrkL in a dose-dependent manner, resulting in
CrkL-association almost as efﬁcient as observed for wild-type NS1.
Thus, we concluded that a p85β-mediated CrkL–p85β–NS1 com-
plex does form in cells expressing an SH3 binding-incompetent
NS1 protein.
Fig. 2. Mutational analysis of the roles of SH3- and p85β-binding by NS1.
(a) Activation of PI3K signaling by wild-type (WT), SH3-binding deﬁcient (AxxA),
or p85β-binding deﬁcient (Y89F) NS1 proteins. Myc-tagged versions of the
indicated NS1 proteins were transfected into Huh7 cells. 48 h later activation of
PI3K signaling was assayed by Western blotting of lysates of the transfected cells
with an antibody speciﬁc for phospho-Akt (top panel). Equal amounts of the
different NS1 proteins in these lysates were conﬁrmed by anti-Myc Western
blotting (middle panel). (b) Co-precipitation of endogenous p85β and transfected
NS1 proteins (WT, AxxA, or Y89F) with endogenous CrkL. Lysates of cells
transfected as in A were subjected to anti-CrkL immunoprecipitation followed by
Western blotting analysis of the immunocomplexes with an anti-p85β (middle
panel) or an anti-Myc (NS1) antibody (bottom panel). Equal NS1 expression in the
total lysates was conﬁrmed as in (a). (c) Competitive disruption of the CrkL–p85β
complex by titration of recombinant NS1–Y89F. Increasing amounts (from 0 μg to
12 μg) of recombinant NS1–Y89F or 12 μg of NS1-AxxA expressed as GST fusion
proteins were added to lysates of cells transfected with biotinylation domain-
tagged CrkL and HA-tagged p85β (total protein amount 200 μg). The amount of
p85β and NS1 proteins associated with CrkL precipitated with streptavidin beads
was examined by Western blotting.
Fig. 3. Reported (a) and hypothesized (b) interactions among the Crk(L), p85β, and
NS1 proteins. Note that all natural NS1 proteins do not contain the SH3 target motif
(PxxP) formed by the NS1 residues P212 and P215. Hence this motif has been
drawn only when it is necessary for the indicated complex. As discussed in the text,
the afﬁnity of the Crk(L) SH3 domain for the NS1 PxxP motif appears to be greater
than its afﬁnity for the p85β PxxP motif. The presence or absence of this motif in
NS1 may therefore determine which of the two alternative trimeric complexes
illustrated in (b) is formed. The references for the previously reported dimeric
complexes shown in (a) are Crk(L)–p85β (Gelkop et al., 2001; Sattler et al., 1997),
NS1–p85β (Hale et al., 2006; Shin et al., 2007), and in (b) NS1–Crk(L) (Heikkinen et
al., 2008).
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Demonstration of a p85β-bridged association of CrkL and the
Mallard NS1-AxxA suggested that similar trimeric Crk(L)–p85β–
NS1 complexes would also be formed in cells expressing NS1
proteins encoded by prototypic viruses, such as A/WSN/33 and A/
Udorn/72, which represent seasonal human IAV strains lacking the
Crk(L) SH3 binding motif. Indeed, when WSN and Udorn NS1
proteins were co-transfected with p85β, they could be co-
precipitated with cellular CrkL as efﬁciently as the Mallard NS1
protein (Fig. 4b). In strong support of the model of the two
alternative CrkL–p85β–NS1 complexes (Fig. 3b), the capacity of
p85β to couple Udorn and WSN NS1 with CrkL completely
depended on the SH3 binding motif of p85β, and was disrupted
by the P294A/P297A mutation. Thus, we conclude that Crk
proteins are also associated with the PI3K-activating NS1/p85β
complexes involving NS1 proteins that lack direct Crk(L) binding
capacity.
To further test the model of two alternative trimeric complexes
(Fig. 3b), we co-expressed all relevant combinations of the
differentially mutated versions of these proteins, and investigated
in parallel which complexes could form (Fig. 5). For these studies
we generated an additional mutant of p85β (V573M), which
prevents the binding of p85β to NS1 (Li et al., 2008). As already
shown for endogenous p85β (Fig. 2b), transfected wild-type p85β-
HA could be co-precipitated with CrkL from wild-type NS1- and
NS1-AxxA-transfected cells (Fig. 5, panel II, lanes 3 and 4), as well
as in the absence of any NS1 (lane 2), whereas expression of NS1–
Y89F inhibited this association (lane 5). In the absence of NS1 the
V573M mutation in p85β did not affect binding to CrkL (lane 10),
but this mutation rendered p85β–CrkL association sensitive to
inhibition also by wild-type NS1 (lane 11). In keeping with the
earlier work (Gelkop et al., 2001; Sattler et al., 1997), disruption of
the SH3 binding site in p85β (P294A, P297A) abolished direct
binding of p85β to CrkL (lane 6). Attesting to the role of NS1 as a
bridging factor between CrkL and p85β in Complex 1 (Fig. 3b) co-
precipitation of p85β-P294A, P297A with CrkL could be rescued by
wild-type NS1 (Fig. 5, lane 7), but not by NS1-AxxA or NS1-Y89F
(lanes 8 and 9). The same was true for co-precipitation of CrkL
with p85β (panel VI). Only wild-type NS1 could mediate pull-
down of CrkL by p85β–P294A, P297A, whereas co-precipitation of
CrkL by wild-type p85β was observed even in the absence of any
NS1. Of note, however, wild-type NS1 further increased CrkL/
p85β-association, attesting to the efﬁcient formation of a trimeric
CrkL–NS1–p85β complex. This effect also evident in the reciprocal
co-IP (panel II), albeit less pronounced presumably because of the
higher relative abundance of transfected p85β compared to
endogenous CrkL.
In addition to the expected coprecipitation pattern of the p85β
variants, the presence of NS1 and its AxxA and Y89F mutants in
the anti-CrkL (panel III) or in the anti-p85β (anti-HA; panel V)
immunocomplexes correlated perfectly with the model presented
in Fig. 3(b). Speciﬁcally, V573M mutation in p85β or Y89F muta-
tion in NS1 prevented interaction of NS1 with p85β, while SH3
binding capacity of NS1 did not play a role. In contrast, whereas
the SH3 binding-competent NS1-WT and NS1–Y89F proteins could
be precipitated with CrkL regardless of the cotransfected p85β
variant, NS1-AxxA failed to associate with CrkL if either the SH3
binding site (P294A, P297A) or the NS1 binding site (V573M) of
p85β was mutated.
To conﬁrm that such trimolecular complexes can assemble as
depicted in Fig. 3b without the assistance of additional CrkL- or
p85β-associated cellular factors, we expressed and puriﬁed full-
length p85β (both wild-type and the P294A/P297A mutant) and
NS1 (both wild-type and the AxxA mutant) proteins, as well as a
CrkL protein fragment containing the SH3 domain in recombinant
Fig. 4. Overexpression of p85β reveals association of CrkL with NS1/p85β com-
plexes involving SH3 binding-incompetent NS1 proteins. (a) Increasing amounts of
HA-tagged p85β was transfected to 293T cells together with wild-type (WT) or
SH3-binding deﬁcient (AxxA) NS1. Proteins associated with anti-CrkL (endogenous)
precipitations from these cells were detected in Western blots with anti-HA (p85β),
anti-CrkL, or anti-NS1 antibodies. The levels of transfected p85β and NS1 in the
total lysates (WCE) were similarly detected. (b) NS1 proteins from Mallard (M),
WSN (W), or Udorn (U) strains were cotransfected to 293T cells together with a
wild-type (WT) or Crk(L) SH3 domain binding-deﬁcient mutant (P294A, P297A)
versions of p85β. The association of these NS1 with anti-CrkL immunocomplexes
was examined as in (a).
Fig. 5. Mutational characterization of the interaction interfaces involved in the
assembly of two alternative trimeric complexes between CrkL, NS1, and p85β.
Different combinations of wild-type and mutated versions of Mallard NS1 and p85β
were transfected into 293T cells as indicated. Immunocomplexes precipitated from
these cells by antibodies against CrkL (endogenous) (panels I-III) or p85β (anti-HA;
panels IV-VI) were examined by probing the Western blot with antibodies against
p85β (anti-HA), NS1, or CrkL as indicated. Expression of NS1 in all NS1-transfected
cells was conﬁrmed by Western blot analysis of total cell lysates (WCE).
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form. Experiments involving mixing of two or three of these
proteins together followed by pull-down analysis of proteins
associated with wild-type or mutant p85β conﬁrmed that Com-
plex I (where NS1 connects p85β and CrkL) as well as Complex II
(where p85β connects NS1 and CrkL) can be assembled in vitro
from puriﬁed recombinant components (Supplementary Fig. 2).
Moreover, conﬁrming our conclusions on the assembly of these
complexes in living cells, SH3 binding-deﬁcient NS1 could associ-
ate with CrkL in Complex II only if the SH3 binding site in p85β
was intact.
In conclusion, these data ﬁrmly established a model where a
trimeric complex involving NS1, CrkL, and p85β can assemble
according to two distinct principles, depending on the SH3 binding
capacity of NS1 (Fig. 3b).
Functional consequences of p85β/CrkL complex rearrangement by
NS1
As already discussed, Crk proteins are naturally associated with
PI3K via SH3-mediated binding to a proline-rich motif in p85β.
Because of this interaction recruitment of CrkL to NS1–p85β
complexes involving SH3 binding defective NS1 proteins was also
observed (Figs. 4 and 5). However, we could detect a p85β-bridged
CrkL–NS1 association (Complex 2) only when p85β was over-
expressed, suggesting that CrkL recruitment to PI3K–NS1 com-
plexes via p85β is less efﬁcient than recruitment via an NS1–CrkL
SH3 interaction. Thus, we reasoned that if the lower PI3K activa-
tion by SH3 binding-deﬁcient NS1 proteins might be rescued by
CrkL overexpression.
To test this idea we transfected wild-type Mallard NS1 and
NS1-AxxA with or without CrkL, and compared the activation of
PI3K in these cells (Fig. 6). Overexpression of CrkL had a relatively
modest enhancing effect on wild-type NS1-induced Akt phosphor-
ylation, whereas the weaker PI3K activation by NS1-AxxA was
signiﬁcantly potentiated by CrkL overexpression. When the natu-
rally Crk(L) binding-deﬁcient NS1 protein from the Udorn strain
was tested, a similar potentiation of PI3K activation by CrkL
overexpression could also be observed. Moreover, we also tested
the capacity of overexpressed CrkI and CrkII to potentiate PI3K/Akt
activation by Crk(L) binding-deﬁcient NS1, and obtained results
that were very similar to those seen with CrkL (data not shown).
Previously it was reported that the SH3 binding function of NS1
is involved in regulation of the c-Abl activity, a tyrosine kinase that
phosphorylates tyrosine residues Y221 and Y207 in Crk and CrkL,
respectively (Hrincius et al., 2014). Moreover, c-Abl could also
phosphorylate p85β (Sattler et al., 1996). While an effective
inhibition of c-Abl activity was evident by a profound suppression
of CrkL tyrosine phosphorylation, we observed no effect on NS1-
induced Akt phosphorylation (Supplementary Fig. 3), thus ruling
out a critical role for c-Abl in this regulation.
In summary, we conclude that the efﬁcient recruitment of Crk
proteins into the PI3K–NS1 complex underlies the enhanced PI3K
activation by SH3 binding competent NS1 proteins. However,
additional qualitative differences between the two alternative
Crk(L)–NS1–p85β might also exist and could favor PI3K activation
in the context of Complex 1.
Discussion
Binding to the p85β regulatory subunit of PI3K is a conserved
function of NS1 proteins of diverse IAV strains (Ehrhardt and
Ludwig, 2009; Hale and Randall, 2007). This interaction leads to
activation of PI3K/Akt signaling, which can contribute to viral
replication and disease pathogenesis (see later). The capacity of
NS1 of certain IAV strains to bind to the SH3 domains of the Crk
adapter proteins is associated with enhanced PI3K activation
(Heikkinen et al., 2008). The same SH3 domain normally couples
Crk proteins to PI3K by binding to a proline-rich target motif in
p85pre (Gelkop et al., 2001; Sattler et al., 1997).
In this study we show that SH3 binding-competent NS1
proteins can displace this natural SH3 interaction, and direct the
assembly of a novel Crk(L)–NS1–p85β complex (“Complex 1”)
where NS1 is the bridging factor. The interaction of p85β with
NS1 lacking the capacity for SH3 binding also takes place in
association with Crk(L), but involves an alternative trimeric com-
plex NS1–p85β–Crk(L) (“Complex 2”) where p85β is the bridging
factor. Because of the low cellular levels of p85β, and the relatively
modest afﬁnity of p85β for the CrkL SH3 domain, Complex 2 could
be physically observed only when p85β was overexpressed.
Indeed, our data suggest that the enhanced PI3K activation in
the context of Complex 1 is caused by a more efﬁcient tethering of
Crk(L) to NS1 and PI3K. In support of this conclusion, overexpres-
sion of CrkL could compensate for this difference, and thereby
potentiate PI3K activation by SH3 binding-deﬁcient NS1.
These results establish that enhancement of NS1-induced PI3K/
Akt signaling by Crk(L) is directly coupled to the PI3K-activating
NS1–p85β interaction, rather than acting somewhere upstream or
downstream in the PI3K/Akt signaling pathway. Previous studies
have found both Crk(L) and p85β in anti-NS1 immunocomplexes
(Heikkinen et al., 2008; Hrincius et al., 2010), but this could also be
explained by distinct dimeric NS1–p85β and NS1–Crk
(L) complexes. In contrast, the combination of our mutagenesis
and co-precipitation approaches provides a deﬁnite proof for
mutual complexes involving all three proteins, and correlates the
assembly of this trimeric complex with enhancemement of PI3K/
Akt activation.
Fig. 6. Effect of CrkL overexpression on PI3K/Akt activation induced by various NS1
proteins. (a) Wild-type Mallard NS1 (WT), NS1-AxxA (AxxA), Udorn NS1 (Udorn) or
an empty control vector (vector) were transfected into Huh7 cells with or without
an expression vector for biotinylation domain-tagged CrkL. Induced PI3K/Akt
signaling in the transfected cells was examined by probing the lysates with an
antibody speciﬁc for phospho-Akt (top panel). The presence of NS1 and CrkL
proteins in these lysates was detected with anti-Myc antibody or labeled strepta-
vidin. The uniform loading of the lysates was controlled by probing with an anti-α-
tubulin antibody (bottom panel). (b) Phospho-Akt signal intensities from (a) and
two similar experiments were quantiﬁed using the Odyssey scanning software, and
the enhanced pAkt signal intensity is shown as fold increase induced by CrkL
overexpression as indicated. Statistical signiﬁcance of the differences were deter-
mined by Student's t-test (*Po0.01).
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Importantly, our results also reveal a general role for Crk
proteins as host cell cofactors in NS1-mediated activation of
PI3K/Akt signaling, which is not limited to NS1 variants carrying
a functional Crk(L) SH3 binding motif. However, the latter have
clearly evolved a more efﬁcient strategy to usurp Crk proteins as
cofactors in PI3K regulation. The mechanistic role of Crk(L) in NS1-
mediated PI3K/Akt activation remains to be fully understood. It is
possible that Crk(L) or an additional Crk(L)-associated protein
would be directly involved in the process where binding of NS1
leads to dismantling of the negative regulation imposed by p85β
on the p110 subunit. Considering the role of Crk(L) as an arche-
typic cellular adapter protein, as well as the ﬂexibility of the
observed Crk(L)–NS1–p85β complex architecture, however, a
perhaps more likely scenario is that Crk(L) serves as an anchor
to localize the NS1–PI3K complex to a subcellular compartment
that is favorable for activation of the PI3K/Akt pathway by NS1.
Indeed, PI3K signaling is complex, involving several alternative
p85 and p110 isoforms that can associate in many different
combinations (Vanhaesebroeck et al., 2010). It is likely that these
different types of PI3K variants operate in overlapping but differ-
ent signaling pathways, and associate with distinct sets of partner
proteins that regulate and target their activities. Thus, it is easy to
envision how Crk(L) could be involved in guiding the NS1–PI3K
complex to a speciﬁc cellular signaling domain that optimally
supports PI3K activation as well as otherwise ensures a cellular
response that maximally beneﬁts the virus.
The NS1 gene of most seasonal IAV strains would need just a
single nucleotide change to acquire the capacity to encode a
functional Crk(L) SH3 binding motif, which therefore would be
expected happen quickly if it provided direct replicative advantage
for the virus. Thus, the reason why viruses like the 1918 pandemic
strain have incorporated this feature into their genome must
reﬂect part of a more complex strategy that they have evolved to
interact with PI3K-dependent pro- and antiviral processes in
their hosts.
Regulation of host cell PI3K activity during different steps of
the IAV life-cycle is a multifaceted process that is not limited to the
action of NS1 (see Ehrhardt and Ludwig, 2009). The role of PI3K
activation by NS1 during IAV replication in cell culture and
pathogenesis in mice has been studied using engineered viruses
with mutant NS1 proteins that cannot bind to p85β. Originally it
was reported that such mutants are attenuated, giving rise to a
smaller plaque size and lower viral titers (Hale et al., 2006; Shin et
al., 2007). More recently a profound reduction in viral replication
and pathogenesis in mouse models of IAV infection was also
reported (Ayllon et al., 2012b; Hrincius et al., 2012). However,
the study by Hale and colleagues showed that the requirement for
NS1-induced PI3K activation is strikingly virus strain dependent.
While the underlying biology remains to be clariﬁed (see Ayllon et
al., 2012a), it is evident that variation elsewhere in the viral
genome can render PI3K activation by NS1 largely or completely
dispensable for IAV replication. On the other hand, only some
(typically avian) strains of IAV encode SH3-binding competent NS1
proteins that can efﬁciently recruit Crk proteins to enhance NS1-
induced PI3K activation (Heikkinen et al., 2008). As shown in the
current study, however, Crk(L)-mediated potentiation of PI3K/Akt
signaling depends entirely on p85β-binding coordinated by the
tyrosine residue 89 of NS1. Thus, the variable capacity for Crk
(L) SH3 binding by NS1 proteins from different IAV provides
another layer of complexity to the strain-speciﬁc variation in host
cell PI3K regulation.
In summary, the data presented in this study provide a detailed
characterization of the Crk(L)–NS1–PI3K multiprotein complex,
and emphasize the role of Crk proteins as host cell cofactors of the
IAV virulence factor NS1. The fact that some IAV have incorporated
a Crk(L) SH3 binding motif in the NS1 protein to take maximal use
of the Crk proteins in order to enhance NS1-mediated PI3K
activation attests the importance of PI3K-regulated host cell
processes for IAV.
Materials and methods
Cells
Human embryonic kidney 293T (ATCC: CRL-11268) and human
hepatocellular carcinoma Huh-7 (a gift from Mark Harris, Uni-
versity of Leeds, UK) cell lines were maintained in Dulbecco's
modiﬁed Eagle's medium high glucose supplemented with 0.6 μg/
ml penicillin, 60 μg/ml streptomycin, 10% fetal bovine serum, and
2 mM glutamine.
Plasmids and recombinant proteins
Plasmid constructs for the myc-NS1 (A/Mallard/Netherlands/
12/2000/H7N3, A/Udorn/72 and A/WSN/33) proteins, GST-NS1,
MBP-NS1 and the C-terminally biotinylated Crk proteins have
been described before (Heikkinen et al., 2008; Kesti et al., 2007).
The cDNA for mouse p85β (Open Biosystems) was cloned into the
pEBB-vector (Tanaka et al., 1995) with an N-terminal HA-tag or a
biotin acceptor domain. Codon changes in NS1 and p85β genes
were generated by standard overlap PCR mutagenesis. GST-NS1
and MBP-NS1 recombinant proteins were produced as previously
described (Heikkinen et al., 2008).
Protein precipitation and detection
For immunoprecipitation and protein pull-down experiments,
293T cells were transfected by a standard calcium phosphate
precipitation method. 48 h after transfection the cells were col-
lected and lysed in 1% NP40 lysis buffer (150 mM NaCl; 50 mM
Tris–HCl, pH 7.9; 1% NP40). Cell lysates were used for immuno-
precipitation with an anti-CrkL or an anti-HA antibody coupled to
Dynabeads protein G magnetic beads (Invitrogen). Alternately
lysates were used for streptavidin pulldown with streptavidin-
coated Dynabeads (Invitrogen). To examine the phosphorylation
status of Akt, Huh7 cells in 6-well plates were transfected with
4 mg of plasmid DNA using Lipofectamine 2000 (Invitrogen)
according to manufacturer's instructions. Cells were serum-
starved for 12 h and 48 h after transfection followed by lysis in
1% NP40 buffer. In Supplementary Fig. 3 the cells were treated
with 20 μM Imatinib for 12 h. Western blots were visualized with
the Odyssey infrared imaging system (LI-COR Biosciences).
Antibodies and inhibitors
The following primary antibodies were used in this study:
mouse anti-Myc (9E10, Santa Cruz Biotechnology), mouse anti-
CrkL (clone 5–6, Millipore), mouse anti-HA (F-7, Santa Cruz
Biotechnology), rabbit anti-phospho Akt(Ser473) (D9E, Cell Signal-
ing Technology), mouse anti-Akt (40D4, Cell Signaling Technol-
ogy), mouse anti-p85β (T15, AbD Serotec), mouse anti-α-tubulin
(DM1A, Sigma-Aldrich) and guinea-pig anti-NS1 (Melen et al.,
2007). Streptavidin IRDye680CW, Streptavidin IRDye800CW,
IRDye680CW goat anti-mouse IgG, IRDye800CW goat anti-mouse
IgG, IRDye680CW goat anti-rabbit IgG, and IRDye800CW goat anti-
rabbit were from LI-COR Biotechnology. IRDye800CW rabbit anti-
guinea pig was from Rockland Immunochemicals. The c-Abl
inhibitor Imatinib was from Sigma-Aldrich.
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